Skip to main content
Premium Trial:

Request an Annual Quote

Compaq to Invest $100M in Life Science Companies

NEW YORK, Sept 26 - Compaq Computer Corporation (NYSE: CPQ) said Tuesday it would invest $100 million in early-stage genomics and bioinformatics companies in order to speed up growth in the life science industry as well as increase its foothold in the sector.

" Now we're expanding our participation in this exciting market by investing in companies in the early stages of their development,” Michael Capellas, Compaq’s president and CEO, said in a statement.

“This is all about fostering discoveries that will impact our everyday lives, while also building long-term strategic relationships in a rapidly growing market," Capellas said.

Compaq of Houston said it would make direct investments in companies as well as invest in venture capital funds targeting the sector. Compaq announced a “significant investment” in Applied Genomic Technology Capital Fund, a venture capital fund in Cambridge, Mass.

Compaq, which has become a leading vendor to the fast-growing genomics sector over the last few years, said it intended to also provide start-ups with early access to its AlphaServer systems and StorageWorks Systems.

These systems are currently used by companies and institutions such as Celera Genomics (NYSE: CRA), MIT's Whitehead Institute, and the Sanger Centre.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.